这是覆盖全国419家医院的罕见病诊疗协作网的日常。北京协和医院作为国家级牵头医院，已建立 中国罕见病诊疗服务信息系统、罕见病多学科"一站式"诊疗模式，成立罕见病医学科、罕见病专科病 房。 从4年缩短到4周以内！这不仅是数字的锐减，更是生命的转机。 这是一场关乎生命的马拉松，各方力量蓄积，并肩在路上。 2026年2月28日，我们迎来第19个国际罕见病日，主题是"不止罕见"。罕见病，又称"孤儿病"，世 界卫生组织将其定义为患病人数占总人口0.65‰至1‰的疾病。目前，全球已知的罕见病有7400余种， 影响着超4.2亿患者的人生轨迹。在中国，这一群体的规模不少于2000万人。 "罕见"的是病，"不罕见"的是爱。面对这道横亘在生命面前的医学"寒冰"，一场与时间赛跑、为生 命护航的"中国行动"，为爱呐"罕"，让爱不凡。 ——从医院诊室出发，让罕见不再"难辨"。 罕见病的诊疗，堪称医学界的"珠穆朗玛峰"。过去确诊平均耗时4年，这是病患家庭难以承受之 重，如今，这块坚冰正在消融。 每周四中午，北京协和医院罕见病会诊中心，总会上演一场"最强大脑"的集结。来自不同学科的顶 尖专家和全国多家罕见病诊疗协作网医院的医生们，共同为一 ...

这是一场关乎生命的马拉松，各方力量蓄积，并肩在路上。 2026年2月28日，我们迎来第19个国际罕见病日，主题是"不止罕见"。罕见病，又称"孤儿病"，世界卫生 组织将其定义为患病人数占总人口0.65‰至1‰的疾病。目前，全球已知的罕见病有7400余种，影响着超 4.2亿患者的人生轨迹。在中国，这一群体的规模不少于2000万人。 "罕见"的是病，"不罕见"的是爱。面对这道横亘在生命面前的医学"寒冰"，一场与时间赛跑、为生命护航 的"中国行动"，为爱呐"罕"，让爱不凡。 ——从医院诊室出发，让罕见不再"难辨"。 罕见病的诊疗，堪称医学界的"珠穆朗玛峰"。过去确诊平均耗时4年，这是病患家庭难以承受之重，如 今，这块坚冰正在消融。 这是覆盖全国419家医院的罕见病诊疗协作网的日常。北京协和医院作为国家级牵头医院，已建立中国罕 见病诊疗服务信息系统、罕见病多学科"一站式"诊疗模式，成立罕见病医学科、罕见病专科病房。 从4年缩短到4周以内！这不仅是数字的锐减，更是生命的转机。 "协作网的核心目标是让患者'罕而不孤'，无论身处何地，都能找到正确的诊疗方向，获得同质化的医疗 服务。"中华医学会罕见病分会主任委员、北京协和医院 ...

中新网上海2月24日电(记者 陈静) "我们的终极目标，是希望通过全社会的共同努力，帮助他们(罕见病 患者)真正回归社会，成为社会大家庭中的一员。"上海市罕见病防治基金会理事长、中华医学会罕见病 分会副主任委员黄国英24日表示，"罕见病不仅仅是医学层面的诊疗问题，更是一个深度的社会和民生 问题。这需要多方力量的共同托举。" 九三学社成员、原上海市政协常委黄鸣指出："目前上海虽然已有诸多罕见病救助机制，但仍然亟需整 体性的协调机制。"她认为，设立罕见病专项基金的核心价值就在于提供制度性的稳定保障。 "资金到位后，如何有效运用是关键。我们需要像社区事务受理中心一样，在基层建立'一门式'或'一窗 式'的服务机构，让患者在第一时间就能提出申请并与基金衔接，确保制度真正落地。"针对罕见病专项 基金具体的运作模式与资助范围，黄鸣提出了极具建设性的"一窗式"构想，她同时强调，"更重要的 是，罕见病专项基金能起到核心枢纽的作用，对现有的沪惠保、基本医保、少儿住院基金、医疗救助及 残障资助等各类保障资源进行有机整合；通过这种整合，能让原本分散的政策形成合力，从而发挥出更 大的保障效应。" 2025年3月1日，《上海市医疗保障条 ...

Core Viewpoint - The article highlights the challenges faced by families of patients with rare diseases in China, particularly focusing on the high costs of medication and the need for systemic support to improve treatment accessibility and affordability [1][2]. Group 1: Challenges in Rare Disease Treatment - The average annual medication cost for patients with Duchenne Muscular Dystrophy (DMD) exceeds 100,000 yuan, creating a significant financial burden for ordinary families [1]. - The difficulties in diagnosis, medication access, and healthcare support are described as "three mountains" that weigh heavily on rare disease patients [1]. - The overall burden of rare disease treatment, including regular check-ups and standardized medication, is reported to be substantial [2]. Group 2: Initiatives and Progress - A rare disease reporting system covering 1.15 billion people has registered 1.64 million cases, indicating progress in tracking and managing rare diseases [2]. - The updated national medical insurance drug list published at the end of 2025 includes over 100 rare disease medications, covering more than 50 types of diseases, providing hope for more families [2]. - Efforts are being made to explore the establishment of a cost compensation mechanism for rare disease medications and to build a supply guarantee network for these drugs [2]. Group 3: Advocacy and Community Engagement - The article emphasizes the importance of gathering diverse opinions to formulate effective solutions for rare disease challenges [2]. - The commitment of healthcare professionals, such as Du Lijun, to advocate for patients and address their needs is highlighted, showcasing a dedication to improving healthcare access [3][4]. - The role of community support and the need for a robust social safety net for special children, including those with rare diseases, is underscored [2].

Core Insights - The article emphasizes the increasing attention and efforts towards rare disease treatment in China, highlighting the government's initiatives and the role of international pharmaceutical companies in improving drug accessibility for patients [2][4][10]. Government Initiatives - The Chinese government has been enhancing the rare disease prevention and treatment system, with the first batch of 121 rare diseases and treatment guidelines released in 2018 [2]. - By 2025, the new national medical insurance drug list will add 13 rare disease medications, covering over 90 types of rare disease drugs, significantly reducing the financial burden on patients [2][4]. - As of the end of 2023, 165 rare disease drugs have been approved in China, covering 92 types of rare diseases [4]. Pharmaceutical Industry Engagement - Multinational pharmaceutical companies, such as AstraZeneca, are actively participating in events like the China International Import Expo (CIIE) to showcase their rare disease drugs, which have been approved in China [2][3]. - AstraZeneca has established a company in Qingdao specifically for the import of rare disease medications, indicating a commitment to the Chinese market [3]. Challenges in Treatment - The article outlines significant challenges faced by rare disease patients, including difficulties in diagnosis, lack of effective treatment options, and high drug costs [3][4][6]. - Currently, only 5% of known rare diseases have effective treatments, leaving many patients without options [4][9]. Insurance and Financial Support - Approximately 100 rare disease medications are included in the national medical insurance drug list, covering 42 types of rare diseases, but patients still face out-of-pocket expenses [4][6]. - The government is encouraged to further reduce the self-payment ratio for rare disease drugs and explore innovative insurance solutions to alleviate financial burdens on patients [6][7]. Collaborative Efforts - The establishment of a rare disease collaboration network involving 419 hospitals aims to improve diagnosis and treatment through a multidisciplinary approach [5][8]. - AstraZeneca supports the establishment of rare disease centers of excellence in provinces to enhance patient referral and diagnosis processes [8]. Future Directions - The article calls for the establishment of an innovative drug fund to support cutting-edge treatments for rare diseases, independent of the standard insurance system [7]. - Continuous policy updates and market innovations are expected to enhance the accessibility and affordability of rare disease medications in China [10][11].

Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.07 billion yuan for the first nine months of 2025, a year-on-year increase of 2.60%, with pharmaceutical manufacturing sales at 18.16 billion yuan and pharmaceutical commerce sales at 196.91 billion yuan, up 2.91% year-on-year [1] - The company achieved a net profit attributable to shareholders of 5.15 billion yuan, reflecting a significant year-on-year growth of 26.96% [1] R&D Investment and Pipeline Progress - The company maintained a high level of R&D investment at 1.73 billion yuan, accounting for 9.52% of pharmaceutical manufacturing sales, with R&D expenses at 1.51 billion yuan [2] - As of the reporting period, the company had 57 new drug pipelines accepted for clinical trials, including 45 innovative drugs [2] - Notable advancements include the NDA submission for BCD-085, a monoclonal antibody for ankylosing spondylitis, and the completion of patient enrollment for the Phase III trial of a traditional Chinese medicine for cervical spondylotic myelopathy [2] Traditional Chinese Medicine Business - The traditional Chinese medicine segment achieved breakthroughs through "innovation while maintaining integrity," with key clinical studies completed for several core products [3] - The company successfully exported its traditional Chinese medicine products to Canada, marking a significant step in internationalization [3] Rare Disease Initiatives - The company views rare disease treatment as a key aspect of its corporate social responsibility, focusing on R&D, supply chain, and ecosystem development [4] - A dedicated rare disease R&D team has been established, with multiple pipelines under development, including SRD4610 for amyotrophic lateral sclerosis [4] - The company has 51 products for rare diseases, covering 67 different rare disease conditions [4] Pharmaceutical Commerce Growth - The pharmaceutical commerce segment continued to grow through innovation, with strategic partnerships with companies like Baxter China and others [5] - The innovative drug business saw sales revenue of 40.7 billion yuan, a year-on-year increase of over 25%, while the import agency business generated 27.6 billion yuan, up over 14% [5] New Retail Strategy and Digital Transformation - The company is advancing its new retail strategy focused on "hospital-side pharmacies + DTP specialty pharmacies," leveraging AI to enhance traditional business operations [6] - The digital upgrade of pharmaceutical services through Shenyang Health aims to provide comprehensive health management services for patients [6]

Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.07 billion RMB for the first three quarters of 2025, marking a year-on-year growth of 2.60% [1] - The company achieved a net profit attributable to shareholders of 5.15 billion RMB, reflecting a significant year-on-year increase of 26.96% [1] Financial Performance - Revenue breakdown: Pharmaceutical manufacturing sales reached 18.16 billion RMB, while pharmaceutical commerce sales were 196.91 billion RMB, with the latter growing by 2.91% year-on-year [1] - Operating cash flow for the period was 2.35 billion RMB, indicating sustained high-quality development [1] R&D Investment - R&D investment totaled 1.73 billion RMB, accounting for 9.52% of pharmaceutical manufacturing sales, with 1.51 billion RMB specifically allocated for R&D expenses [2] - The company has 57 new drug applications in the pipeline, including 45 innovative drugs, with significant progress in clinical trials for several key products [2] Traditional Chinese Medicine (TCM) Business - The TCM segment achieved breakthroughs through evidence-based research and international standardization efforts [3] - New product launches and branding initiatives targeted at younger consumers were implemented, enhancing the company's market presence [3] - Successful export of TCM products to Canada, including the first TCM compound preparation to enter the Canadian market under a Western medicine indication [3] Rare Disease Initiatives - The company is committed to addressing rare diseases through R&D, supply chain optimization, and ecosystem building [4] - A dedicated rare disease R&D team has been established, with multiple drug candidates in various stages of clinical trials [4] - Collaboration with stakeholders to create a comprehensive ecosystem for rare disease prevention and treatment has been initiated [4] Commercial Innovation and Growth - The pharmaceutical commercial segment continued to grow through innovation, strategic partnerships, and digital transformation [6] - Sales from innovative drug products reached 40.7 billion RMB, with a year-on-year growth exceeding 25% [6] - The company is advancing a new retail strategy focused on specialized pharmacies and leveraging AI for traditional business enhancement [6]

Core Insights - The recent 2025 Complement Day Conference gathered nearly 300 top experts from over 10 countries to focus on rare diseases related to the complement system, including PNH, aHUS, gMG, and NMOSD [1][2] - The complement system plays a crucial role in innate immunity, but its dysfunction can lead to various inflammatory or autoimmune diseases, significantly impacting patient quality of life and survival [1] Group 1: Rare Diseases and Their Challenges - PNH, aHUS, gMG, and NMOSD are characterized by complex clinical presentations and high misdiagnosis rates due to insufficient awareness in primary healthcare settings [1] - These diseases progress rapidly and can affect multiple organ systems, leading to severe physical and economic burdens on patients and their families [1] Group 2: Advances in Diagnosis and Treatment - Recent advancements in diagnostic techniques and interdisciplinary collaboration have shifted the treatment of these rare diseases from traditional supportive care to precise targeted therapies [2] - The establishment of a national rare disease diagnosis and treatment network, comprising 419 hospitals, has created a quality control system at multiple levels, supported by a comprehensive case data registry of 1.74 million cases [2] Group 3: Policy and System Development - China has moved from a "policy vacuum" to a critical period of "system construction" in rare disease prevention and treatment, with significant achievements such as the inclusion of 207 rare diseases in the national directory [2] - The national medical insurance directory now covers over 90 rare disease drugs, with additional support measures like tax exemptions and expedited approvals for high-cost medications [2]

Core Insights - The education opportunities for patients with osteogenesis imperfecta, commonly referred to as "porcelain dolls," have significantly improved, but challenges remain to be addressed [1][3][5] Group 1: Education and Social Integration - The 2025 survey report on the living conditions of osteogenesis imperfecta patients highlights a notable improvement in educational opportunities, with school enrollment rates for eligible children rising from 93% in 2017 to 99% [7] - The coverage of accessible toilets in schools increased from 34% to 62%, and the proportion of children attending school independently rose from 6% to 34% [7] - The dropout rate has decreased from 48% to 41%, indicating that more patients are completing compulsory education and pursuing higher education [7] Group 2: Employment and Economic Challenges - The employment rate among the osteogenesis imperfecta community remains low, with only about 45% of respondents having part-time or full-time jobs [9] - Although medical treatment does not significantly impact their work, physical disabilities lead to longer travel times for daily commutes [9] - There is a growing need for job environments and positions that accommodate their physical conditions to enhance employability [9] Group 3: Aging and Future Support - The aging population within the osteogenesis imperfecta community is becoming a concern, with some individuals over 40 beginning to plan for retirement [9] - Most patients prefer home-based care, while some are interested in integrated medical and nursing care to address health and skeletal issues in old age [9] - Experts at the conference emphasized the ongoing social challenges faced by this community, including economic burdens, daily rehabilitation, and the need for social support [11]

Core Viewpoint - The event "2 in 20,000 Encounters - The First National Public Welfare Science Popularization Art Exhibition on Tenosynovial Giant Cell Tumor (TGCT)" aims to raise awareness about TGCT, a rare disease affecting approximately 60,000 new cases annually in China, highlighting its impact on patients' daily lives and mobility [1][2]. Group 1: Disease Overview - TGCT is a non-malignant, locally aggressive tumor primarily affecting individuals aged 20-50, leading to symptoms such as joint swelling, pain, stiffness, and limited mobility [1][2]. - The disease is often misdiagnosed due to its non-specific symptoms, which can resemble other conditions like ganglion cysts and osteoarthritis, resulting in delayed treatment for many patients [2]. Group 2: Treatment and Clinical Needs - Surgical intervention remains the primary treatment for TGCT, with an overall recurrence rate of approximately 46.8% and a median recurrence time of about 12.9 months [2]. - There is a significant unmet clinical need for safe, effective systemic treatments, especially for patients with diffuse TGCT, who face challenges of recurrence and complications [2]. Group 3: Awareness and Community Involvement - The event aims to mobilize social forces and increase public participation in rare disease awareness, emphasizing the need for collaboration among government, medical institutions, enterprises, charitable organizations, and society to build a sustainable ecosystem for rare disease prevention and treatment in China [3].